Catalyst Pharma (CPRX) has released an update.
Santhera Pharmaceuticals’ study on the efficacy and safety of their drug Vamorolone for treating boys with Duchenne Muscular Dystrophy over 48 weeks has been published in the prestigious journal Neurology. The company, which has exclusive rights to commercialize the drug in North America, shared this exciting development in a recent press release.
For further insights into CPRX stock, check out TipRanks’ Stock Analysis page.
